|
|
| 1. |
Aranidipine (MPC‐1304), a New Dihydropyridine Calcium Antagonist: A Review of Its Antihypertensive Action |
| |
Cardiovascular Drug Reviews,
Volume 14,
Issue 1,
1996,
Page 1-16
Kyoichi Ohashi,
Akio Ebihara,
Preview
|
PDF (1006KB)
|
|
ISSN:0897-5957
DOI:10.1111/j.1527-3466.1996.tb00310.x
出版商:Blackwell Publishing Ltd
年代:1996
数据来源: WILEY
|
| 2. |
RES‐701‐1: A Novel Endothelin ETBReceptor Antagonist |
| |
Cardiovascular Drug Reviews,
Volume 14,
Issue 1,
1996,
Page 17-35
Hideaki Karaki,
Yuzuru Matsuda,
Preview
|
PDF (1116KB)
|
|
ISSN:0897-5957
DOI:10.1111/j.1527-3466.1996.tb00311.x
出版商:Blackwell Publishing Ltd
年代:1996
数据来源: WILEY
|
| 3. |
TAK‐044: An Endothelin Receptor Antagonist |
| |
Cardiovascular Drug Reviews,
Volume 14,
Issue 1,
1996,
Page 36-46
Toshifumi Watanabe,
Masahiko Fujino,
Preview
|
PDF (605KB)
|
|
ISSN:0897-5957
DOI:10.1111/j.1527-3466.1996.tb00312.x
出版商:Blackwell Publishing Ltd
年代:1996
数据来源: WILEY
|
| 4. |
Ro 22‐9194: A New Class I Antiarrhythmic Agent |
| |
Cardiovascular Drug Reviews,
Volume 14,
Issue 1,
1996,
Page 47-59
Makoto Murakami,
Yasuyuki Furukawa,
Mitsuyoshi Nakashima,
Shigetoshi Chiba,
Preview
|
PDF (646KB)
|
|
ISSN:0897-5957
DOI:10.1111/j.1527-3466.1996.tb00313.x
出版商:Blackwell Publishing Ltd
年代:1996
数据来源: WILEY
|
| 5. |
Almokalant—A Selective Class III Antiarrhythmic Compound |
| |
Cardiovascular Drug Reviews,
Volume 14,
Issue 1,
1996,
Page 60-83
Börje Darpö,
Olle Almgren,
Preview
|
PDF (1413KB)
|
|
ISSN:0897-5957
DOI:10.1111/j.1527-3466.1996.tb00314.x
出版商:Blackwell Publishing Ltd
年代:1996
数据来源: WILEY
|
| 6. |
KN‐62: A Specific Ca2+/calmodulin‐dependent Protein Kinase Inhibitor as a Putative Function‐searching Probe for Intracellular Signal Transduction |
| |
Cardiovascular Drug Reviews,
Volume 14,
Issue 1,
1996,
Page 84-95
Hiroyoshi Hidaka,
Katsuo Okazaki,
Preview
|
PDF (865KB)
|
|
摘要:
The relationship between changes in intracellular free calcium concentration (Cai2+) and cell functions is becoming more clear, since it has become possible to measure Cai2+in a living cell. There are, however, still unsolved questions concerning the role of Ca2+in cellular signal transmission. It is not easy to relate Ca2+signalling to the functions of a living cell. It is possible to control the amount of Ca2+using calcium channel blockers, but it is still almost impossible to elucidate the relationship between Ca2+and cellular functions by controlling Ca2+signalling.One approach to solving this problem is to develop and use protein kinase inhibitors. Inhibitors specific to Ca2+/calmodulin‐dependent protein phosphorylation, which is one of the important network systems of the Ca2+signalling, attract interest among many researchers. The substances that can control Ca2+signalling include: 1) calcium channel blockers, 2) calmodulin antagonists, and 3) Ca2+/calmodulin‐dependent protein kinase inhibitors. Each substance has a different site of action.In this article, the action of KN‐62, an inhibitor specific for Ca2+/calmodulin protein kinases (CaM kinases) will be desc
ISSN:0897-5957
DOI:10.1111/j.1527-3466.1996.tb00315.x
出版商:Blackwell Publishing Ltd
年代:1996
数据来源: WILEY
|
|
首页
Volume 14 issue 1